Detecting 2-Hydroxyglutarate
Why Enantiomers Matter
| Species | Source | Association |
|---|---|---|
| D-2-HG (R) | Neomorphic IDH1/2 mutations; also minor normal production | Oncogenic; accumulates to millimolar in IDH-mutant tumours |
| L-2-HG (S) | Normal TCA by-product; accumulates in L2HGDH deficiency | Neurological disease, not typically oncogenic |
Important distinction. Achiral LC-MS reports the sum. In IDH-mutant cells the D form dominates so the sum is a reasonable proxy; in IDH-wild-type cells with an acquired metabolic shift the two can move in opposite directions, and the sum is uninterpretable. The appropriate method is chiral.
Part 1 — Methods
| Method | Enantiomer resolution | Sensitivity | Note |
|---|---|---|---|
| Chiral LC-MS/MS (chiral stationary phase) | Yes | High | The reference approach |
| Achiral LC-MS/MS | No | High | Adequate only when D dominates |
| Derivatisation with chiral reagent (e.g. DATAN) | Yes | High | Converts enantiomers to diastereomers, separable on C18 |
| GC-MS with chiral column | Yes | High | Requires derivatisation |
| Enzymatic assay (D-2-HGDH) | Yes, D-specific | Moderate | Useful for confirmation |
| Magnetic resonance spectroscopy (in vivo) | No | Low | Reports total 2-HG; used clinically |
Readout note. The derivatisation approach — reacting 2-HG with a chiral anhydride to form diastereomers — allows separation on a conventional reverse-phase column, which is practical for laboratories without chiral columns. The derivatisation must go to completion, and the reagent must be enantiopure; a partially racemic reagent produces doubled peaks that are easily misread.
Part 2 — Sample Handling
| Step | Requirement | Consequence if omitted |
|---|---|---|
| Quench | Cold, immediate | 2-HG is relatively stable but its precursors are not |
| Extraction | Cold aqueous or organic; avoid strong acid | Acid can lactonise related metabolites |
| Internal standard | Isotope-labelled 2-HG, added before extraction | Recovery unmeasured |
| Storage | −80 °C; avoid repeated freeze–thaw | Drift between runs |
| Medium measurement | Include medium blank | Serum and medium contribute low levels |
| Normalisation | Cell number or protein, stated | Comparisons across conditions distorted |
Caveat on tissue. In tissue, 2-HG is present at different concentrations in tumour and stroma, and bulk measurement averages them. An IDH-mutant tumour with 30% tumour cellularity reports a much lower concentration than the tumour cells actually contain — a point that matters when comparing to in vitro thresholds.
Part 3 — Interference
| Interference | Detail |
|---|---|
| Isobaric compounds | Glutamate and other metabolites can share transition masses; chromatographic separation is required |
| Matrix effects | Medium and serum suppress ionisation differently from standards in water |
| Enantiomer cross-talk | Incomplete separation produces a shoulder that inflates the minor enantiomer |
| Derivatisation by-products | Additional peaks that can co-elute |
| Sample carry-over | 2-HG sticks to some column chemistries |
Part 4 — What the Measurement Supports
| Claim | Requires | Not sufficient |
|---|---|---|
| "IDH mutation produces D-2-HG" | Enantiomer-resolved measurement, mutant versus wild-type | Total 2-HG |
| "2-HG is elevated in this model" | D-2-HG with a wild-type comparator | A single arm |
| "2-HG inhibits TET in these cells" | Concentration plus an epigenetic readout | Concentration alone |
| "The inhibitor reduced 2-HG" | Enantiomer-resolved measurement before and after | Total 2-HG |
| "2-HG is a biomarker in vivo" | MRS or biofluid measurement with validation | Cell culture data |
Part 5 — Common Failures
- • Total 2-HG reported for an IDH-wild-type model.
- • Chiral separation claimed without demonstrating resolution of standards.
- • No internal standard, so recovery and matrix effects are unmeasured.
- • Achiral method used to compare enantiomer ratios.
- • Medium contribution not subtracted.
- • Bulk tissue compared with cell-culture thresholds without correcting for cellularity.
- • MRS values compared directly with LC-MS values, although they measure different volumes and report total 2-HG.
- • Inhibitor effect measured at a single timepoint, before the pool has re-equilibrated.
Part 6 — Where This Article Connects
This is the analytical companion to the oncometabolite article, which covers the dioxygenase logic and the epigenetic readouts. It connects to the succinate model article, where the same compartment problem arises, and to the tracing article, where 2-HG can be followed from labelled glutamine.
If you need 2-HG measured with enantiomer resolution and matrix-matched standards, we can scope the analysis with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
2-HG concentration, enantiomer ratio and recovery vary with genotype, matrix, extraction and method. Chiral resolution must be demonstrated for each method.
A total 2-HG value does not establish the D-enantiomer concentration, and an elevated concentration does not establish dioxygenase inhibition in the cell.
Scientific interpretation and experimental design
- • Two enantiomers, one oncometabolite. Resolve them.
- • Demonstrate the separation. Standards, not assumptions.
- • Matrix-match the standard curve.
- • Subtract the medium.
- • Tissue averages tumour and stroma.
- • MRS reports total, not D.
Selected references for further reading
- • Dang L, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–744.
- • Struys EA, et al. Measurement of urinary D- and L-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography–tandem mass spectrometry after derivatization with diacetyl-L-tartaric anhydride. Clinical Chemistry. 2004;50:1391–1395.
- • Andronesi OC, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Science Translational Medicine. 2012;4:116ra4.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »